Testing the Neurovascular Hypothesis of Alzheimer's Disease: LRP-1 Antisense Reduces Blood-brain Barrier Clearance, Increases Brain Levels of Amyloid-β Protein, and Impairs Cognition
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Decreased clearance is the main reason amyloid-beta protein (Abeta) is increased in the brains of patients with Alzheimer's disease (AD). The neurovascular hypothesis states that this decreased clearance is caused by impairment of low density lipoprotein receptor related protein-1 (LRP-1), the major brain-to-blood transporter of Abeta at the blood-brain barrier (BBB). As deletion of the LRP-1 gene is a lethal mutation, we tested the neurovascular hypothesis by developing a cocktail of phosphorothioate antisenses directed against LRP-1 mRNA. We found these antisenses in comparison to random antisense selectively decreased LRP-1 expression, reduced BBB clearance of Abeta42, increased brain levels of Abeta42, and impaired learning ability and recognition memory in mice. These results support dysfunction of LRP-1 at the BBB as a mechanism by which brain levels of Abeta could increase and AD would be promoted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 1×
“Previous studies have shown that deposits of A β in the brain parenchyma of AD patients consist of mainly A β 42 ; therefore, this isoform is thought to play a major role in AD pathology [7].”
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“Alzheimer’s disease (AD) is the most common cause of dementia among people over the age of 65 [1].”
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 3×
“Immunocytochemistry of brain microvessels from young (2 months) and old (9 months) C57BL/6 wild-type mice revealed that there is a 42% reduction in LRP-1 positive vessels in aged mice [13].”
Ghrelin controls hippocampal spine synapse density and memory performance
Diano, S., Farr, S. A., Benoit, S. C., McNay, E. C., da Silva, I., Horvath, B., Gaskin, F. S., Nonaka, N., Jaeger, L. B., Banks, W. A., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1656 · Cited by 828 · cited 1×
“This behavioral test as described previously [36,37] was used to assess spatial learning in cocktail, random antisense and saline treated animals.”
Self-citationLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Murine tumor necrosis factor alpha is transported from blood to brain in the mouse
Gutierrez, E. G., Banks, W. A., & Kastin, A. J. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90027-v · Cited by 577 · cited 1×
“This method was performed to determine the distribution of the iv cocktail PS-ODNs between brain tissue and the brain capillaries [29,30].”
Self-citationKang, D. E., Pietrzik, C. U., Baum, L., Chevallier, N., Merriam, D. E., Kounnas, M. Z., Wagner, S. L., Troncoso, J. C., Kawas, C. H., Katzman, R., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11013 · Cited by 354
Cited by
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293
From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Self-citationSuppression of glymphatic fluid transport in a mouse model of Alzheimer's disease
Peng, W., Achariyar, T. M., Li, B., Liao, Y., Mestre, H., Hitomi, E., Regan, S., Kasper, T., Peng, S., Ding, F., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.015 · Cited by 580
“Aβ clearance from brain is due to receptor mediated transport at the blood-brain barrier (BBB) and bulk flow of ISF, which are reduced with aging (Banks et al., 2003; Deane et al., 2004; Jaeger et al., 2009; Kress et al., 2014; Zlokovic, 2008a).”
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Self-citationRonaldson, P. T., & Davis, T. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20951995 · Cited by 392
“and recognition memory in mice.(141) Accumulation of Ab plaques can induce inflammatory processes characterized by astrocytosis and microgliosis.”
BackgroundErickson, M. A., & Banks, W. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014647 · Cited by 378
Self-citationMetabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Pathophysiology of the Neurovascular Unit: Disease Cause or Consequence?
Stanimirovic, D. B., & Friedman, A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.25 · Cited by 346
Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
“would move into the lysosome for degradation, or to the other side of cells for transcytosis (16, 79–82), several other groups have also reported LRP1-mediated A clearance in animal models (83, 84).”
BackgroundHealthy aging and the blood–brain barrier
Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M., & Erickson, M. A. (2021) · Nature Aging · doi:10.1038/s43587-021-00043-5 · Cited by 292
Self-citationKanekiyo, T., & Bu, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00093 · Cited by 281
Jaeger, L. B., Dohgu, S., Sultana, R., Lynch, J. L., Owen, J. B., Erickson, M. A., Shah, G. N., Price, T. O., Fleegal-Demotta, M. A., Butterfiled, D. A., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.01.017 · Cited by 281
Self-citationOxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
“Therefore, up-regulation of RAGE via oxidative stress-induced neuro-inflammation potentially increases brain levels of Ab by increased Ab influx and decreased Ab efflux (Jaeger et al. 2009b).”
BackgroundThe Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zlokovic, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 278
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease
Yoon, S.-S., & AhnJo, S.-M. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.245 · Cited by 205
Hladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Self-citationMontagne, A., Nikolakopoulou, A. M., Huuskonen, M. T., Sagare, A. P., Lawson, E. J., Lazic, D., Rege, S. V., Grond, A., Zuniga, E., Barnes, S. R., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00073-z · Cited by 188
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184
Self-citationErickson, M. A., Hartvigson, P. E., Morofuji, Y., Owen, J. B., Butterfield, D. A., & Banks, W. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-150 · Cited by 145
“We have found that this method of Aβ labeling shows specificity for LRP-1-dependent BBB efflux from brain [7].”
BackgroundMethodInfluentialSelf-citationBrain macrophage development, diversity and dysregulation in health and disease
Silvin, A., Qian, J., & Ginhoux, F. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01053-6 · Cited by 137
Rivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
Morley, J. E., & Banks, W. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091576 · Cited by 108
Self-citationFunctional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92
“Lrp1 gene silencing reduced the clearance of intracerebroventricularlyinjected Aβ across the BBB in wildtype mice (Jaeger et al., 2009).”
BackgroundAging alters mRNA expression of amyloid transporter genes at the blood-brain barrier
Osgood, D., Miller, M. C., Messier, A. A., Gonzalez, L., & Silverberg, G. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.011 · Cited by 63
“LRP-1 antisense blockade of LRP-1 function at the BBB reduced Ab clearance, increased Ab brain levels, and impaired learning and memory in mice (Jaeger et al., 2009).”
Chen, J., Xiang, P., Duro-Castano, A., Cai, H., Guo, B., Liu, X., Yu, Y., Lui, S., Luo, K., Ke, B., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02426-1 · Cited by 45
A closer look at the mycobiome in Alzheimer’s disease: Fungal species, pathogenesis and transmission
Phuna, Z. X., & Madhavan, P. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15599 · Cited by 41
“Another plausible route is via olfactory nerve, particularly in the context of olfactory dysfunction during the progression from mild cognitive impairment (MCI) to AD (Jung et al., 2019; Kotecha et al., 2018). ‘Olfactory hypothesis’ was proposed in 1988, where the pathogens can enter the brain via olfactory tract (Man…”
BackgroundMadadi, S., Schwarzenbach, H., Saidijam, M., Mahjub, R., & Soleimani, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0354-3 · Cited by 41
Goncalves, A., & Antonetti, D. A. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00386-0 · Cited by 22
“In a separate study, blocking Lrp1 expression with antisense mRNA resulted in similar accumulation of radiolabeled Aβ-peptides in the brain and impaired learning and memory [183].”
BackgroundCholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets
Wang, N.-Q., Sun, P.-X., Shen, Q.-Q., & Deng, M.-Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04672-w · Cited by 19
“Inhibition of LRP1 expression using antisense oligonucleotides has been shown to cause endothelial damage in the mouse brain, significantly reducing Aβ clearance rates and increasing Aβ burden in brain tissue, which impairs learning and memory recognition in these mice [90].”
Metadata
- Authors
- Jaeger, L. B., Dohgu, S., Hwang, M. C., Farr, S. A., Murphy, M. P., Fleegal-DeMotta, M. A., Lynch, J. L., Robinson, S. M., Niehoff, M. L., Johnson, S. N., Kumar, V. B., & Banks, W. A.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2009-07-01
- Volume
- 17
- Issue
- 3
- Pages
- 553-570
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1508243540
- Cited by
- 133
- References
- 13
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.